Latest News





11-25-15 New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting
11-11-15 Zogenix to Participate in Stifel 2015 Healthcare Conference
11-09-15 Zogenix Provides Corporate Update and Reports Third Quarter 2015 Financial Results

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.